Ensign Peak Advisors
TBIO

Ensign Peak Advisors’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Ensign Peak Advisors’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-45,327
Closed -$836K – 1913
2020
Q4 		$836K Sell
45,327
-44,750
-50% -$801K ﹤0.01% 1470
2020
Q3 		$1.23M Buy
90,077
+78,556
+682% +$1.21M ﹤0.01% 1221
2020
Q2 		$206K Hold
11,521
– – ﹤0.01% 1579
2020
Q1 		$115K Sell
11,521
-26,328
-70% -$216K ﹤0.01% 1569
2019
Q4 		$308K Buy
+37,849
New +$349K ﹤0.01% 1589

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

Ensign Peak Advisors's TBIO Position: Q1 2021 in Review

Ensign Peak Advisors sold out of Translate Bio, Inc. Common Stock (TBIO) in Q1 2021, closing a stake of 45,327 shares — an estimated $836K sold.

Ensign Peak Advisors first reported a position in TBIO in Q4 2019 and held it in 5 quarters. The position peaked at $1.23M in Q3 2020. 146 funds tracked by Wall St. Rank hold TBIO as of Q1 2021.

  • Ensign Peak Advisors reported no remaining Translate Bio, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Ensign Peak Advisors sold 45,327 Translate Bio, Inc. Common Stock shares in Q1 2021, an estimated $836K.
  • Ensign Peak Advisors first reported a position in Translate Bio, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
  • Ensign Peak Advisors's Translate Bio, Inc. Common Stock position peaked at $1.23M in Q3 2020.
  • 146 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q1 2021.

Based on Ensign Peak Advisors's 13F filing for Q1 2021, filed 12 May 2021.